Crescent Biopharma, Inc (CBIO) insider trading
Every open-market stock purchase and sale by Crescent Biopharma, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $20M over the last 12 months (1 buy).
- Insiders sold $1.2M over the last 12 months (7 sales).
- Last insider buy: Fairmount Funds Management LLC (10% owner), $18.2M, 10 months ago.
Last 12 months: insiders bought $20M (1 buy) and sold $1.2M (7 sales). Last close $18.00 on Jun 4, 2026.
Recent CBIO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 22, 2026 | Joshua T Brumm (CEO) | Sold | $761K |
| Jun 22, 2026 | Jonathan McNeill (COO) | Sold | $370K |
| Jun 22, 2026 | Jan Pinkas (C-suite exec) | Sold | $23.2K |
| Jun 22, 2026 | Ellie Eunkyung Im (C-suite exec) | Sold | $21.9K |
| Jun 22, 2026 | Barbara Harlin Bispham (Officer) | Sold | $21.9K |
| Jun 22, 2026 | Richard William Scalzo (CFO) | Sold | $20K |
| Jun 22, 2026 | Ryan Lynch (Officer) | Sold | $8.4K |
| Jun 2, 2026 | Fairmount Funds Management LLC (10% owner) | Bought (not open market) | — |
| Jun 2, 2026 | Susan Moran (Director) | Bought (not open market) | — |
| Jun 2, 2026 | David Charles Lubner (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Alexandra Balcom (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Jonathan Violin (Director) | Bought (not open market) | — |
| Dec 15, 2025 | Christopher Grant Doughty (C-suite exec) | Bought (not open market) | — |
| Dec 15, 2025 | Joshua T Brumm (CEO) | Bought (not open market) | — |
| Dec 15, 2025 | Christopher Grant Doughty (C-suite exec) | Bought (not open market) | — |
| Dec 15, 2025 | Jonathan McNeill (COO) | Bought (not open market) | — |
| Dec 15, 2025 | Ryan Lynch (Officer) | Bought (not open market) | — |
| Dec 15, 2025 | Jonathan McNeill (COO) | Bought (not open market) | — |
| Dec 15, 2025 | Jonathan McNeill (COO) | Bought (not open market) | — |
| Dec 15, 2025 | Jan Pinkas (C-suite exec) | Bought (not open market) | — |
| Dec 15, 2025 | Ellie Eunkyung Im (C-suite exec) | Bought (not open market) | — |
| Dec 15, 2025 | Ellie Eunkyung Im (C-suite exec) | Bought (not open market) | — |
| Dec 15, 2025 | Ryan Lynch (Officer) | Bought (not open market) | — |
| Dec 15, 2025 | Ryan Lynch (Officer) | Bought (not open market) | — |
| Dec 15, 2025 | Barbara Harlin Bispham (Officer) | Bought (not open market) | — |
Who's trading CBIO
- Ellie Eunkyung Im, C-suite exec: sold $21.9K (1 sale), last Jun 22, 2026
- Joshua T Brumm, CEO: sold $761K (1 sale), last Jun 22, 2026
- Ryan Lynch, Officer: sold $8.4K (1 sale), last Jun 22, 2026
- Jonathan McNeill, COO: sold $370K (1 sale), last Jun 22, 2026
- Richard William Scalzo, CFO: sold $20K (1 sale), last Jun 22, 2026
- Barbara Harlin Bispham, Officer: sold $21.9K (1 sale), last Jun 22, 2026
- Jan Pinkas, C-suite exec: sold $23.2K (1 sale), last Jun 22, 2026
- Jonathan Violin, Director: other filings, last Jun 2, 2026
- Alexandra Balcom, Director: other filings, last Jun 2, 2026
- Fairmount Funds Management LLC, 10% owner: bought $20M (2 buys), last Jun 2, 2026
- David Charles Lubner, Director: other filings, last Jun 2, 2026
- Susan Moran, Director: other filings, last Jun 2, 2026
- Christopher Grant Doughty, C-suite exec: other filings, last Dec 15, 2025
Get free alerts when an insider at Crescent Biopharma, Inc files a new trade →